European Journal of Biomedical and Pharmaceutical Sciences

GUGULIPIDS, A NOVEL THERAPY FOR DYSLIPIDEMIA: COMPARATIVE ANALYSIS TO STANDARD REGIMEN

Kriti Malhotra, P. K. Agarwal* and Sonam Bhatia

ABSTRACT

Raised levels of lipids especially LDL-C are documented risk factors for cardiovascular disorders. Use of hypolipidemic drugs mainly Statins are mainstay in the treatment of dyslipidemias. Herbal drug Gugulipid carries hypolipidemic properties which in combination to Rosuvastatin may prove beneficial to such patients. Sixty patients with dyslipidemia were randomly allocated into Group I and II. Group I patients were administered Rosuvastatin 10 mg OD and Gugulipid 250 mg TDS with meals whereas Group II was administered Rosuvastatin 10 mg alone for six weeks. Baseline lipid levels were recorded and were compared to lipid levels at the end of six weeks. Primary end point was percent change in the lipid parameters of both the treatment groups. Our study concluded that the percent change at six weeks in the various parameters in Group I was superior to that in Group II patients. Also the combination demonstrated a substantial percent increase in the HDL-C levels as compared to the other study group. Both regimes were safe and well tolerated by all patients.

Keywords: CVD, Rosuvastatin, Gugulipid, Lipid profile.